Sublingual Misoprostol for labour augmentation
Keywords:Augmentation to delivery interval, Labour augmentation, Sublingual misoprostol
Background: Labour dystocia is associated with a number of adverse maternal and neonatal outcomes. Augmentation of labour is a commonly used intervention in cases of labour dystocia. Misoprostol is an inexpensive and stable prostaglandin E1analogue. Present study was done to see the effectiveness of sublingual misoprostol for labour augmentation and foeto-maternal outcome.
Methods: Total 100 labouring women of term gestation were taken and divided in two groups: group A (study group) and group B (control group). In study group 25mcg sublingual misoprostol given 4 hourly till adequate uterine contractions developed, i.e. >3 contractions in 10 minutes, each lasting for 40-45 seconds. A maximum of 200mcg of misoprostol or 8 doses were used and in group B no drug was given for augmentation of labour. Maternal and foetal outcome were observed in both groups.
Results: Augmentation to delivery interval was very short in group A in comparison to group B. Maternal and foetal outcome were almost same in both groups.
Conclusions: Sublingual misoprostol is a safe and effective drug for augmentation of labour leading to early delivery without any major side effects.
Vogel JP, West HM, Dowswell T. Titrated oral misoprostol for augmenting labour to improve maternal and neonatal outcomes. Cochrane Database of Systematic Reviews. 2013;9:CD010648.
Selin L, Wallin G, Berg M. Dystocia in labour–risk factors, management and outcome: a retrospective observational study in a Swedish setting. Acta Obstetricia Et Gynecologica Scandinavica. 2008;87(2):216-21.
New U.S. Food and Drug Administration labelling on Cytotec (misoprostol) use and pregnancy. ACOG Committee Opinion No. 283.Obstet Gynecol 2003; 101(5):1049-50.
Rebecca Allen, Barbara M O' Brien. Uses of Misoprostol in Obstetrics and Gynaecology. Rev Obstet Gynecol. 2009;2(3):159-68.
Ho M, Cheng SY, Li TS. Oral Misoprostol solution compared with intravenous oxytocin for labour augmentation. Obstet Gynecol. 2010;116(3):612-18.
Bleich AT1, Villano KS, Lo JY, Alexander JM, McIntire DD, Leveno KJ. Oral misoprostol for labor augmentation: a randomized controlled trial. Obstet Gynecol. 2011;118(6):1255-60.
Siwatch S, Doke G, Kalra J, Bagga R. Sublingual vs. oral misoprostol for labour induction. J Postgrad Med Edu Res. 2014;48(1):33-36.
Wilson S, Das S. Oxytocin versus oral Misoprostol for augmentation of labour, associated complications and effect on neonatal wellbeing. Int J Reprod Contracept Obstet Gynecol. 2018;7(8):3338-42.
Patel A, Gilles JM, Moffett D, Mahram R, Diro M, Burkett G. Can misoprostol be interchanged with oxytocin for augmentation of labor?. Obstet Gynecol. 2000;95(4):S10.
Cheng SY. Individualized misoprostol dosing for labor induction or augmentation: A review. World J Obstet Gynecol. 2013;2(4):80-6.
Maliha S, Shagufta SS, Sobia NM. Augmentation of labour- A Comparison of oral misoprostol and intravenous titrated oxytocin infusion, J Rawalpindi Med College (JRMC); 2013;17(2):247-50.
WHO recommendation on the use of oral misoprostol for labour augmentation. Available at https://extranet.who.int/rhl/topics/preconception-pregnancy-childbirth-and-postpartum-care/care-during-childbirth/care-during-labour-1st-stage/who-recommendation-use-oral-misoprostol-labour-augmentation
Villano KS, Lo JY, Alexander JM, McIntire DD, Leveno KJ. A dose-finding study of oral misoprostol for labor augmentation. Am J Obstet Gynecol. 2011;204(6):560-e1.
Gattás DS, da Silva Junior JR, Souza AS, Feitosa FE, de Amorim MM. Misoprostol administered sublingually at a dose of 12.5 μg versus vaginally at a dose of 25 μg for the induction of full-term labor: a randomized controlled trial protocol. Reproduct Health. 2018;15(1):65.